Form 8-K · Current Report · Filed 2026-07-31
Moderna Reports Q2 2026 Financial Results and Pipeline Updates
Moderna, Inc. reported second quarter 2026 financial results with total revenue of $145 million, GAAP net loss of $(0.8) billion, and GAAP EPS of $(1.97). The company reiterated its plan for up to 10% revenue growth in 2026 and improved its 2026 operating expense outlook by approximately $0.2 billion. Moderna anticipates potential approval of its seasonal influenza vaccine candidate, mFLUSIVA, with an August 5th PDUFA date. The company also announced that its norovirus vaccine candidate, mRNA-1403, did not meet statistical criteria for early success at the Phase 3 interim analysis and is preparing to enroll an additional cohort. Corporate updates include the appointment of Ester Banque as Chief Commercial Officer and Michael McDonnell to the Board of Directors.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-26-000147
- CIK
- 0001682852
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$57.92
Since filing
-5.4%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, MRNA insiders reported 13 Form 4 transactions — net selling of $2.6M.
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.